A TEAD2-driven endothelial-like program shapes basal-like differentiation and metastasis of pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Gastroenterology"
DOI: 10.1053/j.gastro.2023.02.049
Abstract: BACKGROUND AND AIMS Pancreatic ductal adenocarcinoma (PDA), with its highly metastatic propensity, is one of the most lethal subtypes of pancreatic cancer. Although recent large-scale transcriptomic studies have demonstrated that heterogeneous gene expressions play an… read more here.
Keywords: pancreatic cancer; basal like; pda cells; pda ... See more keywords
Abstract LB-B05: Targeting IDH1 inhibits survival and growth of pancreatic cancer cells
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-lb-b05
Abstract: Pancreatic ductal adenocarcinoma (PDA) cells have elevated levels of reactive oxygen species (ROS) compared to adjacent normal cells. Although ROS play a role in pancreatic carcinogenesis, the accumulation of excess ROS at later stages of… read more here.
Keywords: targeting idh1; inhibits survival; survival growth; pda cells ... See more keywords
Coordinated transcriptional and catabolic programs support iron dependent adaptation to RAS-MAPK pathway inhibition in pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-22-0044
Abstract: The mechanisms underlying metabolic adaptation of pancreatic ductal adenocarcinoma (PDA) cells to pharmacological inhibition of RAS-MAPK signaling are largely unknown. Using transcriptome and chromatin immunoprecipitation profiling of PDA cells treated with the MEK inhibitor, Trametinib… read more here.
Keywords: ras mapk; inhibition; adaptation; iron ... See more keywords